Status: Recruiting
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
This is a Phase 2 placebo-controlled study to evaluate the safety and tolerability of different doses of EDG-15400 in adults with heart failure with preserved ejection fraction (HFpEF).
Participants needed: 90
Trial details
Phase: Phase 2Age: 30-84Biological sex: AllType: InterventionalSponsor: Edgewise Therapeutics, Inc.Updated: Aug 31, 2026Locations: 25
Eligibility criteria
Males and nonpregnant females, ages ≥30 to <85 years of age at screening [+6]
Known diagnosis of hypertrophic cardiomyopathy (HCM) [+5]